Immune Pharmaceuticals Inc.
IMNP
IMNP was delisted on the 25th of July, 2018.
15 hedge funds and large institutions have $360K invested in Immune Pharmaceuticals Inc. in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
25% more funds holding
Funds holding: 12 → 15 (+3)
19% less capital invested
Capital invested by funds: $444K → $360K (-$83.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$180K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$77K |
| 3 |
VF
Virtu Financial
New York
|
+$23.5K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$22.4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$20.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$41K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $237K | +$180K | +189,081 | +84% |
|
|
2
UBS Group
Zurich,
Switzerland
| $50K | +$77K | +80,952 | +1,234% |
|
|
CS
3
Credit Suisse
Zurich,
Switzerland
| $14K | +$22.4K | +23,504 | New |
|
|
VF
4
Virtu Financial
New York
| $14K | +$23.5K | +24,681 | New |
|
5
Geode Capital Management
Boston,
Massachusetts
| $12K | – | – | – |
|
|
6
Bank of America
Charlotte,
North Carolina
| $12K | +$20.5K | +21,594 | New |
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $8K | +$13.6K | +14,251 | New |
|
8
JP Morgan Chase
New York
| $7K | +$11K | +11,510 | New |
|
|
FDCDDQ
9
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $3.99K | – | – | – |
|
|
AG
10
Advisor Group
Phoenix,
Arizona
| $2K | – | – | – |
|
|
TSS
11
Two Sigma Securities
New York
| – | -$41K | -26,975 | Closed |
|
12
Morgan Stanley
New York
| – | +$47 | +49 | +980% |
|
IMNP Hedge Fund Activity: Q4 2017 in Review
15 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q4 2017, worth a combined $360K — down 19% from $444K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IMNP positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, adding an estimated $180K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $41K sold.
- 15 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q4 2017, up from 12 in Q3 2017.
- Funds reported $360K of Immune Pharmaceuticals Inc. stock for Q4 2017, down 19% quarter-over-quarter.
- 5 funds opened new Immune Pharmaceuticals Inc. positions in Q4 2017 and 2 closed out, a net change of +3 holders.
- The largest Immune Pharmaceuticals Inc. buyer in Q4 2017 was Vanguard Group, an estimated $180K added.
- The largest Immune Pharmaceuticals Inc. seller in Q4 2017 was Two Sigma Securities, an estimated $41K sold.
Based on aggregated 13F filings for Q4 2017.